Wasilczyk Cezary
Medical Department, Wasilczyk Medical Clinic, ul. Kosiarzy 37/80, 02-953 Warszawa, Poland.
J Clin Med. 2024 Apr 24;13(9):2475. doi: 10.3390/jcm13092475.
: Anterior cruciate ligament (ACL) tears account for 40% to 50% of all ligamentous knee injuries. Most patients with ACL ruptures undergo surgical treatment. There is currently no objective, well-documented, repeatable, and standardized nonsurgical method for ACL tear treatment. This study aimed to investigate ACL outcomes in patients who underwent a novel nanosurgery and bioengineering treatment (NSBT) for an ACL tear. : This was a double-blind randomized trial including 44 patients with a history of traumatic knee injury and a confirmed ACL tear. The final sample comprised 40 patients who met all the eligibility criteria. The patients were divided into two groups: the treatment group (n = 30) and the control group (n = 10). The treatment group underwent nanosurgery with an ultrasound-guided injection of modified platelet-rich plasma (PRP) using human cell memory (RP-hCM). The control group was treated with an ultrasound-guided PRP injection into the joint capsule. At baseline and post-treatment, all patients underwent both ultrasonography and magnetic resonance imaging (MRI), and the following clinical variables were assessed: the WOMAC score, the Lysholm knee score, the visual analog scale score, and knee instability. In most patients, the clinical outcome was verified using nanoscopy. : The median WOMAC, VAS, and LKS scores, as well as knee instability, improved significantly 12 weeks after the procedure in the treatment group ( < 0.001). We found a significantly larger improvement in the assessed parameters in the treatment group compared to the control group ( < 0.001). In the treatment group, all the patients had good and very good clinical outcomes, while 90% of the patients had a normal ACL signal in a follow-up MRI scan. In the control group, a physical examination revealed no changes in knee stability after treatment. : This study showed that there is a significant difference in patient experience and the duration of recovery for patients with ACL tears treated with NSBT. The novel nonsurgical method was shown to be repeatable, objective, well documented, standardized, and highly effective.
前交叉韧带(ACL)撕裂占所有膝关节韧带损伤的40%至50%。大多数ACL断裂患者接受手术治疗。目前尚无客观、有充分文献记载、可重复且标准化的非手术方法治疗ACL撕裂。本研究旨在调查接受新型纳米手术和生物工程治疗(NSBT)的ACL撕裂患者的ACL治疗效果。 :这是一项双盲随机试验,纳入44例有膝关节外伤史且确诊为ACL撕裂的患者。最终样本包括40例符合所有入选标准的患者。患者分为两组:治疗组(n = 30)和对照组(n = 10)。治疗组接受纳米手术,通过超声引导注射使用人细胞记忆的改良富血小板血浆(PRP)(RP-hCM)。对照组接受超声引导下向关节囊内注射PRP治疗。在基线和治疗后,所有患者均接受超声检查和磁共振成像(MRI),并评估以下临床变量:WOMAC评分、Lysholm膝关节评分、视觉模拟量表评分和膝关节不稳情况。在大多数患者中,使用纳米显微镜验证临床结果。 :治疗组术后12周时,WOMAC、VAS和LKS评分中位数以及膝关节不稳情况均有显著改善(<0.001)。我们发现治疗组评估参数的改善明显大于对照组(<0.001)。治疗组所有患者的临床结果均为良好和非常好,而90%的患者在随访MRI扫描中ACL信号正常。对照组经体格检查发现治疗后膝关节稳定性无变化。 :本研究表明,NSBT治疗的ACL撕裂患者在患者体验和恢复时间方面存在显著差异。这种新型非手术方法具有可重复性、客观性、有充分文献记载、标准化且高效。